DCT

2:26-cv-11341

Teva Neuroscience Inc v. Lupin Ltd

Key Events

Amended Complaint

complaint Intelligence

I. Executive Summary and Procedural Information

Parties & Counsel:
- Plaintiff: Teva Neuroscience, Inc. (Delaware) and Auspex Pharmaceuticals LLC (Delaware)
- Defendant: Lupin Limited (Republic of India), Lupin, Inc. (Delaware), and Lupin Pharmaceuticals, Inc. (Delaware)
- Plaintiff’s Counsel: Walsh Pizzi Oreilly Falanga LLP
Case Identification: Teva Neuroscience, Inc. v. Lupin Limited, 2:26-cv-11341, D.N.J., 09/22/2026
Venue Allegations: Venue is alleged to be proper in the District of New Jersey because Defendant Lupin Limited is a foreign corporation subject to personal jurisdiction in the district, and because the other Lupin defendants allegedly committed, aided, or participated in acts of infringement that will lead to foreseeable harm in New Jersey.
Core Dispute: Plaintiff alleges that Defendant’s submission of an Abbreviated New Drug Application (ANDA) to market generic versions of Plaintiff's AUSTEDO XR® (deutetrabenazine) products infringes twelve U.S. patents.
Technical Context: The technology relates to deutetrabenazine, a deuterated form of tetrabenazine, and its use in pharmaceutical compositions and methods for treating hyperkinetic movement disorders, such as chorea associated with Huntington's disease and tardive dyskinesia.
Key Procedural History: This is a patent infringement action under the Hatch-Waxman Act, triggered by Defendant Lupin's submission of ANDA No. 221686 to the FDA. The action was initiated after Plaintiffs received notice letters from Lupin, dated July 20, 2026, and September 11, 2026, which contained Paragraph IV certifications asserting that the patents-in-suit are invalid, unenforceable, or will not be infringed by Lupin's proposed generic products.

Case Timeline

Date	Event
2015-03-06	Priority Date (’996, ’772, ’291, ’917, ’244, ’858 Patents)
2017-01-24	Issue Date (’780 Patent)
2017-03-15	Priority Date (’386, ’232 Patents)
2020-06-10	Priority Date (’488, ’075, ’598 Patents)
2021-03-30	Issue Date ('996 Patent)
2021-11-23	Issue Date ('386 Patent)
2022-04-26	Issue Date ('488 Patent)
2022-06-14	Issue Date ('772 Patent)
2022-09-20	Issue Date ('291 Patent)
2023-01-31	Issue Date ('917 Patent)
2023-05-16	Issue Date ('244 Patent)
2023-11-14	Issue Date ('232 Patent)
2024-06-25	Issue Date ('858 Patent)
2026-03-31	Issue Date ('075 Patent)
2026-04-14	Issue Date ('598 Patent)
2026-07-20	Lupin's First Notice Letter to Plaintiffs
2026-09-11	Lupin's Second Notice Letter to Plaintiffs
2026-09-22	Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 9,550,780 - "Formulations Pharmacokinetics of Deuterated Benzoquinoline Inhibitors of Vesicular Monamine Transporter 2"

Issued January 24, 2017 Compl. ¶31

The Invention Explained

Problem Addressed: The complaint does not provide sufficient detail from the patent's background section to analyze the specific problem addressed Compl. ¶¶30-35
The Patented Solution: The patent claims a specific solid-state form of deutetrabenazine (d6-tetrabenazine), which is a deuterated analog of a drug used for movement disorders (Compl. ¶¶1; Compl. ¶35). The invention is defined as "crystalline d6-tetrabenazine Form I" and is characterized by specific peaks in an X-ray diffractogram, which is a common method for identifying unique crystalline structures of a chemical compound Compl. ¶35 This suggests the solution is a stable, pure, and identifiable form of the active pharmaceutical ingredient.
Technical Importance: Obtaining a specific, stable crystalline form of a drug is often critical for pharmaceutical development, as it can affect the drug's stability, manufacturability, and pharmacokinetic properties Compl. ¶31

Key Claims at a Glance

The complaint asserts independent claim 1 Compl. ¶117
Essential elements of claim 1:
- A compound that is crystalline d6-tetrabenazine Form I
- having deuterium enrichment of no less than about 1%, and
- having an X-ray diffractogram comprising peaks, in terms of 2θ±0.2, at 6.5, 12.2, 14.4, 22.4 and 23.4; or
- a pharmaceutically acceptable salt or hydrate thereof Compl. ¶35
The complaint does not explicitly reserve the right to assert dependent claims for the '780 patent.

U.S. Patent No. 10,959,996 - "Methods for the Treatment of Abnormal Involuntary Movement Disorders"

Issued March 30, 2021 Compl. ¶37

The Invention Explained

Problem Addressed: The patent background describes a "substantial need for effective treatments for movement disorders" like chorea associated with Huntington's disease, noting that existing therapies are only partially meeting this need '996 Patent, col. 1:19-2:22
The Patented Solution: The patent discloses new dosage regimens for deutetrabenazine, a deuterium-substituted drug, for treating abnormal movement disorders '996 Patent, abstract Specifically, the invention provides a defined method for safely transitioning a patient from the older drug, tetrabenazine, to the newer, deuterated drug, deutetrabenazine, by specifying exact corresponding daily dosage amounts for the switch '996 Patent, col. 8:1-8:65 This provides a clear clinical protocol for the change in therapy.
Technical Importance: This method provides physicians with a specific, clinically tested protocol for switching patients between related drugs, which is intended to maintain therapeutic effect while managing safety and tolerability during the transition period '996 Patent, col. 8:1-8:65

Key Claims at a Glance

The complaint asserts independent claim 1 Compl. ¶127
Essential elements of claim 1:
- A method of transitioning a human from tetrabenazine to deutetrabenazine for the treatment of chorea associated with Huntington's disease, comprising:
- a) discontinuing a daily amount of tetrabenazine; and
- b) administering an initial daily amount of deutetrabenazine the next day to the human,
- wherein specific pairs of daily tetrabenazine amounts and initial deutetrabenazine amounts are recited (e.g., "wherein the daily amount of tetrabenazine is 12.5 mg and the initial total daily amount of deutetrabenazine is 6 mg; or...") Compl. ¶41
The complaint does not explicitly reserve the right to assert dependent claims for the '996 patent.

U.S. Patent No. 11,179,386 - "Analogs of Deutetrabenazine, Their Preparation and Use"

Issued November 23, 2021 Compl. ¶43

Technology Synopsis: The patent addresses the need for high-quality deutetrabenazine compositions by claiming a pharmaceutical tablet that contains a specific, low level of a particular impurity known as "Compound 2" Compl. ¶47 The claim defines the maximum allowable amount of this impurity (not more than 0.15 area %) as determined by a specific High-Performance Liquid Chromatography (HPLC) method, thereby ensuring the purity and stability of the final drug product Compl. ¶47 The chemical structure for Compound 2 is provided in the complaint, showing it to be a degradation product of deutetrabenazine Compl. p. 10
Asserted Claims: The complaint asserts independent claim 1 Compl. ¶137
Accused Features: The complaint alleges that Lupin's ANDA Products, which are deutetrabenazine tablets, will infringe the '386 patent Compl. ¶137

U.S. Patent No. 11,311,488 - "Osmotic Dosage Forms Comprising Deutetrabenazine and Methods of Use Thereof"

Issued April 26, 2022 Compl. ¶49

Technology Synopsis: The patent claims a "once daily osmotic oral dosage form" for deutetrabenazine, designed for controlled release Compl. ¶53 The invention is a sophisticated tablet structure with a bi-layer core (an "active layer" with the drug and a "push layer" that swells), all enclosed in a semipermeable membrane with a laser-drilled port for drug exit, and an optional immediate-release coating Compl. ¶53 This design aims to provide a specific pharmacokinetic profile suitable for once-a-day dosing.
Asserted Claims: The complaint asserts independent claim 1 Compl. ¶147
Accused Features: The complaint alleges that Lupin's oral extended-release tablets will infringe the '488 patent (Compl. ¶¶112; Compl. ¶147).

U.S. Patent No. 11,357,772 - "Methods for the Treatment of Abnormal Involuntary Movement Disorders"

Issued June 14, 2022 Compl. ¶55

Technology Synopsis: The patent claims a method for treating abnormal involuntary movement through a specific dose-titration regimen for deutetrabenazine Compl. ¶59 The method involves administering an initial daily dose, assessing the patient's response and tolerability after about one week, and then systematically increasing or decreasing the dose in defined increments (e.g., 6 mg/day) to optimize therapeutic control and patient safety Compl. ¶59
Asserted Claims: The complaint asserts independent claim 1 Compl. ¶157
Accused Features: The complaint alleges that the use of Lupin's ANDA Products according to its proposed labeling will infringe the '772 patent Compl. ¶159

U.S. Patent No. 11,446,291 - "Methods for the Treatment of Abnormal Involuntary Movement Disorders"

Issued September 20, 2022 Compl. ¶61

Technology Synopsis: This patent claims a method of transitioning a patient from tetrabenazine to deutetrabenazine specifically for the treatment of tardive dyskinesia Compl. ¶65 Similar to the '996 patent, it specifies a protocol of discontinuing the old drug and starting the new drug the next day, with a list of precise, corresponding dosage pairs for the switch Compl. ¶65
Asserted Claims: The complaint asserts independent claim 1 Compl. ¶167
Accused Features: The complaint alleges that the use of Lupin's ANDA Products in accordance with its proposed labeling will infringe the '291 patent Compl. ¶169

U.S. Patent No. 11,564,917 - "Methods for the Treatment of Abnormal Involuntary Movement Disorders"

Issued January 31, 2023 Compl. ¶67

Technology Synopsis: The patent claims a method of treating tardive dyskinesia in a specific patient sub-population, defined by baseline electrocardiogram (ECG) values (QTcF value not greater than 450 ms for males or 460 ms for females) Compl. ¶71 The method comprises administering a low dose of deutetrabenazine (≤ 24 mg) and requires the treatment to result in improved motor function with a minimal increase in the QTcF value (less than 5 ms), indicating a focus on cardiovascular safety Compl. ¶71
Asserted Claims: The complaint asserts independent claim 1 Compl. ¶177
Accused Features: The complaint alleges that the use of Lupin's ANDA Products according to its proposed labeling will infringe the '917 patent Compl. ¶179

U.S. Patent No. 11,648,244 - "Methods for the Treatment of Abnormal Involuntary Movement Disorders"

Issued May 16, 2023 Compl. ¶73

Technology Synopsis: This patent claims a method of treating tardive dyskinesia in specific patient populations defined by age and history of dopamine receptor antagonist use (e.g., ≥60 years old with ≥1 month of use, or <60 years old with ≥3 months of use) Compl. ¶77 The method involves administering a total daily amount of deutetrabenazine between 24 mg and 48 mg, and requires the outcome to be an improvement in motor function with "no clinically significant adverse event" Compl. ¶77
Asserted Claims: The complaint asserts independent claim 1 Compl. ¶187
Accused Features: The complaint alleges that the use of Lupin's ANDA Products according to its proposed labeling will infringe the '244 patent Compl. ¶189

U.S. Patent No. 11,813,232 - "Analogs of Deutetrabenazine, Their Preparations and Use"

Issued November 14, 2023 Compl. ¶79

Technology Synopsis: The patent claims a manufacturing process for a deutetrabenazine tablet that limits the formation of an impurity, "Compound 2" Compl. ¶83 The process starts with a drug substance containing not more than 0.15 area-% of Compound 2 and results in a final drug product that has no more than 0.4 area-% of the impurity after one month of storage at room temperature, ensuring product stability Compl. ¶83 The complaint also asserts claim 2, a product-by-process claim for the tablet made by this process Compl. ¶84 Compl. ¶197
Asserted Claims: The complaint asserts independent claims 1 and 2 Compl. ¶197
Accused Features: The complaint alleges that the manufacture and use of Lupin's ANDA Products will infringe the '232 patent Compl. ¶197

U.S. Patent No. 12,016,858 - "Methods for the Treatment of Abnormal Involuntary Movement Disorders"

Issued June 25, 2024 Compl. ¶86

Technology Synopsis: This patent claims a method of treating abnormal involuntary movement using a specific dose-titration regimen for deutetrabenazine, starting with an initial dose of 12 mg per day Compl. ¶90 The method involves assessing the patient's response after a week and then systematically increasing the dose by 6 mg/day or more if control is inadequate and the dose is tolerable, with an option to decrease the dose if not tolerated Compl. ¶90
Asserted Claims: The complaint asserts independent claim 1 Compl. ¶207
Accused Features: The complaint alleges that the use of Lupin's ANDA Products according to its proposed labeling will infringe the '858 patent Compl. ¶209

U.S. Patent No. 12,589,075 - "Osmotic Dosage Forms Comprising Deutetrabenazine and Methods of Use Thereof"

Issued March 31, 2026 Compl. ¶92

Technology Synopsis: The patent claims a method of administering a once-daily osmotic dosage form of deutetrabenazine for treating a hyperkinetic movement disorder Compl. ¶96 The claim details the specific structure of the osmotic tablet, which is substantially identical to the structure claimed in the '488 patent, including active and push layers, a semipermeable membrane, a port, and an immediate-release coating with specific particle sizes Compl. ¶96
Asserted Claims: The complaint asserts independent claim 1 Compl. ¶217
Accused Features: The complaint alleges that the use of Lupin's ANDA Products, which are oral extended-release tablets, will infringe the '075 patent (Compl. ¶¶112; Compl. ¶219).

U.S. Patent No. 12,599,598 - "Osmotic Dosage Forms Comprising Deutetrabenazine and Methods of Use Thereof"

Issued April 14, 2026 Compl. ¶98

Technology Synopsis: The patent claims a method of transitioning a patient from a twice-daily (bid) deutetrabenazine treatment to a once-daily osmotic dosage form of deutetrabenazine Compl. ¶102 This method is for maintaining control of abnormal involuntary movement and involves administering the last twice-daily dose, and on the next day, administering the total daily dose as a single osmotic dosage form with the specific structural features recited in the '488 and '075 patents Compl. ¶102
Asserted Claims: The complaint asserts independent claim 1 Compl. ¶227
Accused Features: The complaint alleges that the use of Lupin's ANDA Products according to its proposed labeling will infringe the '598 patent Compl. ¶229

III. The Accused Instrumentality

Product Identification

The accused instrumentalities are "Lupin's ANDA Products," which are generic versions of Plaintiffs' AUSTEDO XR® (deutetrabenazine) products for which Lupin Limited submitted ANDA No. 221686 to the FDA Compl. ¶1

Functionality and Market Context

The accused products are identified as oral extended-release tablets containing deutetrabenazine as the active ingredient Compl. ¶111 Compl. ¶112 The complaint specifies that Lupin sought approval for 48 mg and 18 mg dosage strengths and alleges on information and belief that Lupin will seek approval for additional strengths, including 6 mg, 12 mg, 24 mg, 30 mg, 36 mg, and 42 mg Compl. ¶106 Compl. ¶108 Compl. ¶110
The purpose of Lupin's ANDA submission is to obtain FDA approval for the commercial manufacture, use, and sale of its generic deutetrabenazine products in the United States prior to the expiration of the Patents-in-Suit (Compl. ¶¶1; Compl. ¶105). This action is a statutory act of infringement under 35 U.S.C. § 271(e)(2) designed to resolve patent disputes before the generic product enters the market Compl. ¶116

IV. Analysis of Infringement Allegations

The complaint contains chemical structure diagrams for deutetrabenazine and an impurity, Compound 2, which are relevant to the infringement allegations for patents such as the '386 and '232 patents Compl. p. 10 Compl. p. 15

'780 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A compound that is crystalline d6-tetrabenazine Form I	The complaint alleges on information and belief that Lupin's ANDA Products contain deutetrabenazine that is the claimed crystalline Form I.	¶111; ¶117	The complaint does not provide this detail.
having deuterium enrichment of no less than about 1%,	The complaint alleges on information and belief that the deutetrabenazine in Lupin's ANDA Products meets this enrichment level.	¶111; ¶117	The complaint does not provide this detail.
and having an X-ray diffractogram comprising peaks, in terms of 2θ±0.2, at 6.5, 12.2, 14.4, 22.4 and 23.4;	The complaint alleges on information and belief that the deutetrabenazine in Lupin's ANDA Products has this specific X-ray diffractogram profile.	¶111; ¶117	The complaint does not provide this detail.
or a pharmaceutically acceptable salt or hydrate thereof.	The complaint alleges Lupin's ANDA Products are or contain a salt or hydrate of the claimed compound.	¶111; ¶117	The complaint does not provide this detail.

'996 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A method of transitioning a human from tetrabenazine to deutetrabenazine for the treatment of chorea associated with Huntington's disease, comprising:	The complaint alleges that the use of Lupin's ANDA Products in accordance with its proposed labeling would direct or encourage this method of treatment.	¶129	col. 8:1-8
a) discontinuing a daily amount of tetrabenazine; and b) administering an initial daily amount of deutetrabenazine the next day to the human,	It is alleged that Lupin's proposed product labeling will instruct physicians and patients to discontinue tetrabenazine and start administering Lupin's deutetrabenazine product.	¶129	col. 8:1-8
wherein the daily amount of tetrabenazine is 12.5 mg and the initial total daily amount of deutetrabenazine is 6 mg; or [other specific dosage pairs]	The complaint alleges that Lupin's proposed labeling will instruct users to perform the transition according to the specific dosage conversion pairs recited in the claim.	¶129	col. 9:60-10:4

Identified Points of Contention

Evidentiary Questions ('780 Patent): For the '780 patent's compound claims, a central issue will be evidentiary. The allegations are made "on information and belief" Compl. ¶117 The case may turn on what discovery reveals about the actual physical and chemical properties of Lupin's drug substance, specifically whether it is crystalline Form I as defined by the claimed X-ray diffraction peaks.
Scope and Inducement Questions ('996 Patent): For the '996 patent's method claims, a primary question will be whether Lupin's proposed product label will induce infringement. This raises the question of whether the label will explicitly instruct or merely inform physicians about the specific dosage-pair transitioning method required by the claim language. The analysis will depend on the precise wording of Lupin's proposed label, which is not included in the complaint.

V. Key Claim Terms for Construction

'780 Patent

The Term: "crystalline d6-tetrabenazine Form I"
Context and Importance: This term defines the specific polymorphic form of the drug substance. Proving that Lupin's product is or contains this exact form is essential for a finding of literal infringement of claim 1. Practitioners may focus on this term because polymorphism can be a key area of dispute in pharmaceutical patent litigation, often requiring complex expert analysis to resolve.
Intrinsic Evidence for Interpretation:
- Evidence for a Broader Interpretation: The complaint does not provide language from the patent that would support a broader interpretation.
- Evidence for a Narrower Interpretation: The claim itself provides a narrow, specific definition by explicitly listing the required X-ray diffractogram peaks (e.g., "peaks...at 6.5, 12.2, 14.4, 22.4 and 23.4") Compl. ¶35 This provides a precise, objective standard for identifying "Form I" and may be used to argue against any broader definition.

'996 Patent

The Term: "transitioning"
Context and Importance: This term is the active step of the method claim. The dispute will likely center on what actions constitute "transitioning" and whether Lupin's product label induces users to perform those actions. The construction of this term will be critical for the induced infringement analysis.
Intrinsic Evidence for Interpretation:
- Evidence for a Broader Interpretation: The patent's detailed description discusses new dosage regimens for treating movement disorders generally, not just in the context of switching from another drug '996 Patent, abstract This could support an argument that "transitioning" is just one exemplary use of the patented methods of administration.
- Evidence for a Narrower Interpretation: Claim 1 itself narrowly defines "transitioning" by linking it to the specific act of "discontinuing a daily amount of tetrabenazine; and administering an initial daily amount of deutetrabenazine the next day" at specific, recited dosage pairs '996 Patent, col. 8:1-8:65 This language suggests that "transitioning" is not a general concept but is strictly limited to the specific drug-switching protocol recited in the claim.

VI. Other Allegations

Indirect Infringement: The complaint alleges that Lupin will actively induce infringement of the patents-in-suit. This allegation is based on the claim that the use of Lupin's ANDA Products "in accordance with and as directed by Lupin's proposed labeling for those products would infringe" the asserted claims Compl. ¶119 Compl. ¶129 The complaint also alleges contributory infringement, stating that Lupin's products are "especially made or adapted for use in infringing" the patents and are "not suitable for substantial non-infringing use" Compl. ¶121 Compl. ¶131
Willful Infringement: The complaint alleges that Lupin has acted "with full knowledge" of the patents-in-suit and "without a reasonable basis for believing that it would not be liable for infringing" Compl. ¶123 Compl. ¶133 This allegation of willfulness is based on Lupin's knowledge of the patents, as evidenced by its filing of a Paragraph IV certification against them as required by the Hatch-Waxman Act.

VII. Analyst’s Conclusion: Key Questions for the Case

A central issue for the composition and formulation patents (e.g., '780, '386, '488, '232) will be one of evidentiary proof: What will discovery and testing of Lupin's ANDA product reveal about its precise physical and chemical properties? The case may turn on factual comparisons between Lupin's product and the specific claim limitations regarding crystalline form, impurity profiles, and osmotic dosage components.
A key question for the method of use patents (e.g., '996, '772, '291) will be one of induced infringement: Does the language in Lupin's proposed drug label actively instruct or merely describe the specific methods of transitioning, titrating, and treating patients recited in the claims, and does that language meet the legal standard for inducement?
A cross-cutting issue will be one of claim scope and validity: Given the large number of patents covering different facets of the same drug (the compound, its formulations, and its methods of use), the litigation may involve significant disputes over whether the claims of later-issued patents are non-obvious or not anticipated by the disclosures of the earlier patents in the same family.